No Fast Route To EU Market For Dova's Avatrombopag
Dova’s avatrombopag, which was recently approved in the US under priority review, has been refused an accelerated assessment in the EU.
You may also be interested in...
Fourteen new products have been added to the European Medicines Agency’s list of medicines under review for marketing authorization across the EU.
The European Medicines Agency’s pharmacovigilance committee has recommended more restrictions on the use of Richter’s Esmya because of concerns over the risk of serious liver damage.
There has been a sharp fall in the number of companies seeking accelerated assessment for their investigational products at the European Medicines Agency. One such company that has asked – Dova Pharmaceuticals – is staying silent on the outcome of its request.